HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

thorium- 227- p- isothiocyanato- benzyl- DOTA- trastuzumab

a low-dose-rate alpha particle-emitting radioimmunoconjugate; DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

Also Known As:

(227)Th-p-isothiocyanato-benzyl-DOTA-trastuzumab

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Borrebæk, Jørgen: 1 article (02/2011)
2.	Dahle, Jostein: 1 article (02/2011)
3.	Heyerdahl, Helen: 1 article (02/2011)
4.	Krogh, Cecilie: 1 article (02/2011)
5.	Larsen, Åsmund: 1 article (02/2011)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 02/01/2011 - "To evaluate the cytotoxic effects of low-dose-rate alpha particle-emitting radioimmunoconjugate (227)Th-p-isothiocyanato-benzyl-DOTA-trastuzumab ((227)Th-trastuzumab [where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]) internalized by breast and ovarian cancer cell lines in order to assess the potential of (227)Th-trastuzumab as a therapeutic agent against metastatic cancers that overexpress the HER2 oncogene. "
2.	Neoplasms (Cancer) 02/01/2011 - "To evaluate the cytotoxic effects of low-dose-rate alpha particle-emitting radioimmunoconjugate (227)Th-p-isothiocyanato-benzyl-DOTA-trastuzumab ((227)Th-trastuzumab [where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]) internalized by breast and ovarian cancer cell lines in order to assess the potential of (227)Th-trastuzumab as a therapeutic agent against metastatic cancers that overexpress the HER2 oncogene. "

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Acids
3.	Trastuzumab (Herceptin)
4.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid